Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
290 participants
INTERVENTIONAL
2005-12-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW677954
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1.
* Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1.
* Subjects whose plasma LDL C concentration does not require treatment according to the NCEP ATP III guidelines at Screening Visit 1.
Exclusion Criteria
* History of cardiovascular disease
* Diagnosis of genetic lipid disorders
* History of muscle pain
* History of cancer
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Córdoba, , Argentina
GSK Investigational Site
San Juan, , Argentina
GSK Investigational Site
Kippa-Ring, Queensland, Australia
GSK Investigational Site
Meadowbrook, Queensland, Australia
GSK Investigational Site
Elizabeth Vale, South Australia, Australia
GSK Investigational Site
Keswick, South Australia, Australia
GSK Investigational Site
Camperdown, Victoria, Australia
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
San José, , Costa Rica
GSK Investigational Site
Ahmedabad, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Chennai, , India
GSK Investigational Site
Mumbai, , India
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Durango, Durango, Mexico
GSK Investigational Site
Pachuca, Hidalgo, Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Mexico City, , Mexico
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Christchurch, , New Zealand
GSK Investigational Site
Rotorua, , New Zealand
GSK Investigational Site
Karachi, , Pakistan
GSK Investigational Site
Lahore, , Pakistan
GSK Investigational Site
Brasov, , Romania
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Deva, , Romania
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
S.-Petresburg, , Russia
GSK Investigational Site
Košice, , Slovakia
GSK Investigational Site
Košice, , Slovakia
GSK Investigational Site
Alicante, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Granada, , Spain
GSK Investigational Site
Granada, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Móstoles/Madrid, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Tarrasa, Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Statistical Analysis Plan
View DocumentDocument Type: Clinical Study Report
View DocumentDocument Type: Individual Participant Data Set
View DocumentDocument Type: Dataset Specification
View DocumentDocument Type: Informed Consent Form
View DocumentDocument Type: Study Protocol
View DocumentDocument Type: Annotated Case Report Form
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADG103440
Identifier Type: -
Identifier Source: org_study_id